Future Health Biobank

What Future Health Biobank does

Future Health Biobank is a UK-headquartered private stem cell bank that processes, tests, and stores cord blood, cord tissue, and dental pulp stem cells for expectant parents and families. Founded in 2001 and operated by Future Health Technologies Limited (a private limited company registered in England and Wales), the company maintains its main laboratory at its Nottingham Science and Technology Park headquarters and a second state-of-the-art laboratory in Switzerland. The company self-identifies as the UK's largest and Europe's first accredited cord blood stem cell bank, claims to have served more than 100,000 families across 40+ countries, and markets itself as one of the world's most accredited stem cell banks under AABB, HTA, MHRA, ISO, BSI, and Swissmedic certifications.

The product portfolio combines three core recurring banking services — Cord Blood Banking, Cord Tissue Banking, and Dental Pulp Banking — with three diagnostic offerings: the Vision Non-Invasive Prenatal Test (NIPT) for chromosomal screening from 10 weeks of pregnancy, the Outlook Newborn Screening Test for predisposition to conditions such as lactose intolerance, coeliac disease, and medication-induced deafness, and a Dietary Screening service. Cord blood stem cells are marketed as applicable to over 85 standard medical treatments, while cord tissue stem cells are cited as in use across 300+ clinical trials. Processing and storage occur in physically secured laboratories in the UK and Switzerland, with sample release and transportation coordinated globally.

Revenue is generated through a hybrid model: upfront collection and processing fees plus recurring annual storage charges on the installed base of stored samples for the banking line, and one-time fees for genetic testing services. Go-to-market is predominantly direct-to-consumer via the company website, phone sales, baby shows, paid search across Google/Bing/Yahoo, leaflet distribution, and content marketing, supplemented by referrals from doctors, midwives, and hospitals. A field phlebotomist network coordinates sample collection at birth, and the company operates wholly-owned regional subsidiaries in the UAE, Vietnam, Pakistan, Kazakhstan, Ecuador, and Paraguay to localize sales, collection, and support.

Name

Future Health Biobank

Legal name

Future Health Technologies Limited

Website

https://futurehealthbiobank.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

101–250 employees

Short description

Future Health Biobank is a UK-headquartered private stem cell bank that collects, processes, and stores cord blood, cord tissue, and dental pulp stem cells, alongside genetic screening services, for expectant parents and families across 40+ countries.

Ownership category

akta.pro rank

Product category

Stem Cell Banking and Genetic Screening Services

NAICS

Blood and Organ Banks (621991), Medical and Diagnostic Laboratories (62151)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industry

Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

Keywords

• Stem cell banking
• Cord blood storage
• Cord tissue banking
• Prenatal genetic testing
• Newborn genetic screening

Headquarters

HQ city

Nottingham

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Stem Cell Storage Services: Recurring annual fees for storage of cord blood, cord tissue, and dental pulp stem cells. Initial collection and processing fees plus ongoing annual storage charges.
2. Genetic Testing Services: One-time fees for NIPT, dietary screening, and newborn screening tests performed on collected samples or through separate test kits.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Future Health Biobank collects, processes, and stores umbilical cord blood, umbilical cord tissue, and dental pulp stem cells for families, providing long-term cryogenic storage for potential future therapeutic use. The company complements these banking services with accredited genetic diagnostic tests including the Vision Non-Invasive Prenatal Test (NIPT), Outlook Newborn Screening, and Dietary Screening for babies and children.

Product overview

Future Health Biobank operates as a private family stem cell bank offering a comprehensive suite of banking and genetic screening services. The core portfolio includes three stem cell banking products—Cord Blood Banking, Cord Tissue Banking, and Dental Pulp Banking—which allow families to store stem cells from birth or from milk teeth for potential future medical use. Complementing the banking services is a range of diagnostic offerings including the Vision Non-Invasive Prenatal Test (NIPT), Outlook Newborn Screening Test, and Dietary Screening services that provide genetic insights for families. The company operates as a direct-to-consumer service with state-of-the-art laboratories in the UK and Switzerland, serving customers in over 40 countries worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Vision: Non-Invasive Prenatal Test (NIPT) service for genetic screening during pregnancy
• Outlook
• Dietary Screening

Products and services

• Cord Blood Banking Private stem cell banking service that collects, processes, and stores umbilical cord blood at birth for potential future medical use. Cord blood stem cells can treat over 85 medical conditions including leukaemia and thalassemia. Targeted at expectant parents seeking biological insurance for their child.
• Cord Tissue Banking Banking service for umbilical cord tissue stem cells, which have been used in over 300 clinical trials to regenerate and repair bone, cartilage, and other bodily tissues. Collected and stored alongside cord blood as part of the same package. Targeted at expectant parents seeking broader regenerative medicine potential.
• Dental Pulp Banking Stem cell banking service that collects and stores stem cells extracted from children's milk teeth. Dental pulp contains mesenchymal stem cells that can regenerate and repair body tissue, bone, and cartilage for potential future medical treatments. Targeted at parents of young children losing milk teeth.
• Vision Non-Invasive Prenatal Test (NIPT) Fully accredited non-invasive prenatal genetic test that analyses a maternal blood sample to screen for chromosomal conditions. Includes complete genome testing with sex identification available from 10 weeks of pregnancy. Targeted at expectant parents seeking early genetic reassurance.
• Outlook Newborn Screening Test Genetic newborn screening test that screens for predisposition to lactose intolerance, coeliac disease, bitter taste sensitivity, and medication-induced deafness. Available as a mouth swab kit or integrated with the cord blood storage package. Targeted at parents of newborns seeking proactive genetic insight.
• Dietary Screening Genetic screening service for babies and children to detect predisposition towards lactose intolerance, coeliac disease, and bitter taste sensitivity. Uses a simple mouth swab collection method. Targeted at parents wanting early dietary intolerance identification.
• Laboratory Screenings General laboratory screening services covering various genetic and diagnostic tests offered through the company's accredited laboratories. Targeted at consumers seeking accredited diagnostic testing beyond the named core tests.

Quantifiable outcome

• Cord blood stem cells are used in over 85 standard medical treatments
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• King Hussein Cancer Centre (Jordan)coreStrategic or Co-development PartnerTreatment center where Laith Abu Areesh's cord blood stem cell transplant was performed. The hospital received the released stem cell sample from Future Health Biobank for the transplant procedure treating Fanconi's Anemia.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cells4Life: UK-based private cord blood and tissue stem cell bank offering nearly identical services (cord blood, cord tissue, and increasingly dental pulp banking) to expectant parents. Cells4Life is the closest direct competitor in Future Health's home UK market.
• Smart Cells: UK-headquartered private stem cell bank specializing in cord blood and tissue banking, with international distribution. Directly comparable product, customer segment (expectant parents), and pricing model.
• Cryo-Cell International: One of the oldest and largest US-based private cord blood banks, also offering cord tissue and menstrual blood banking. Comparable service model and AABB accreditation profile, with overlap in international cord blood banking services.
• Cord Blood Registry (CBR): Largest US private cord blood bank, now part of CooperCompanies. Directly comparable in product (cord blood and tissue banking), customer segment, and subscription storage model.
• ViaCord: US private cord blood bank owned by Revvity (formerly PerkinElmer). Offers cord blood and cord tissue banking to expectant parents with a comparable recurring storage revenue model.
• Americord Registry: US-based private cord blood and tissue bank offering comparable banking packages and add-on genetic services. Direct overlap in target customer, product, and pricing structure.
• Cryo-Save (now BioLife Solutions / Salient Bio): European-headquartered family stem cell storage company (formerly Cryo-Save AG) historically operating across multiple European countries. Direct overlap in cord blood/tissue banking to families across Europe.
• New England Cord Blood Bank: US private and public hybrid cord blood bank with AABB accreditation. Comparable in banking services and international sample release capabilities.

Broad incumbents

• Natera: Large US genetic testing company whose Panorama NIPT and Vistara products compete directly with Future Health's Vision NIPT. Broader portfolio across reproductive health but overlaps significantly in prenatal genetic screening.

Others

• Illumina: Dominant DNA sequencing platform provider whose technology underpins most NIPT and newborn screening services, including Future Health's own offerings. An enabling/infrastructure peer rather than direct competitor.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/futurehealthuk
• Facebookfacebook.com/FutureHealthBiobankUK
• LinkedInlinkedin.com/company/future-health-biobank

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Future Health Biobank